Medical

Good News, Orphan Drug Status Granted By The FDA For Ezurpimtrostat, a Cutting Edge Drug For Liver Cancer!

The FDA has recently granted orphan drug designation to Ezurpimtrostat, a PPT-1 inhibitor for the treatment of patients with hepatocellular carcinoma (HCC).

Medical

New Research: Cracking The Targeted Drug Resistance Puzzle And Eliminating Cancer Cells Before They Evolve!

Many lung cancer patients will be detected by genetic testing to carry an EGFR mutation, and these patients can often control their tumours with EGFR-targeted drugs. Although targeted drugs are effective and have fewer side effects than chemotherapy, resistance to them inevitably occurs, after which they no longer work.

Medical

Study Shows That a Blood Pressure Drug Combined With Radiotherapy Improves Outcomes In Locally Advanced Pancreatic Cancer

Pancreatic cancer is known to be a highly fatal and incurable type of cancer known as the "king of cancers". Currently, the only possible cure for pancreatic cancer is the complete surgical removal of the tumour tissue. Once the cancer has spread beyond the pancreatic organ, the patient's treatment options are very limited.

Apparatus

Inventory Of Fda-Approved Adc Drugs

The global ADC drug market will be approximately $5.2 billion by 2021

Medical

Breast Cancer: a Brighter Future For Patients As New Cutting-Edge Drugs Continue To Emerge!

With more and more new cutting-edge drugs emerging, the standard treatment paradigm for breast cancer is now rapidly changing, and the future is looking brighter for patients.

Apparatus

"New 'Breakthrough' Alzheimer's Drug Approved: Slows Brain Decline By 27%, But $26,500/Year Pricing Controversial

Eisai and Biogen have partnered to develop Leqembi and have priced it at $26,500 per year.